Checkpoint Therapeutics’ (CKPT) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $4.80 price objective on the stock, down from their previous price objective of $9.00.

Several other research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday, December 16th. Lake Street Capital increased their target price on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th.

Checkpoint Therapeutics Stock Down 0.5 %

NASDAQ CKPT opened at $3.98 on Monday. The stock has a market capitalization of $194.36 million, a P/E ratio of -2.16 and a beta of 1.41. Checkpoint Therapeutics has a 52-week low of $1.38 and a 52-week high of $4.50. The firm has a 50-day moving average price of $3.13 and a 200 day moving average price of $3.10.

Insider Buying and Selling at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the transaction, the chief executive officer now directly owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. This represents a 6.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO William Garrett Gray sold 268,432 shares of Checkpoint Therapeutics stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the completion of the sale, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at approximately $4,141,343.54. This trade represents a 20.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 582,336 shares of company stock worth $2,156,801 in the last quarter. 2.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Checkpoint Therapeutics by 160.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after acquiring an additional 80,000 shares during the last quarter. Walleye Capital LLC bought a new stake in Checkpoint Therapeutics during the third quarter valued at $148,000. State Street Corp increased its stake in Checkpoint Therapeutics by 32.2% during the third quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after purchasing an additional 23,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Checkpoint Therapeutics by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after buying an additional 124,787 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Checkpoint Therapeutics during the third quarter worth about $30,000. 22.00% of the stock is owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.